Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SGI-110 in Advanced Hepatocellular Carcinoma After Sorafenib Failure
2012-003977-24Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Dec 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in hepatocellular carcinoma (HCC), sponsored by Astex Pharmaceuticals. Primary endpoint: Disease control rate at 16 weeks. Started Dec 2013; status: completed.
02
Drugs
guadecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2012-003977-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003977-24.